|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Among the down-regulated miRNAs in SCI, 21, 19 and 20 miRNAs were potentially associated with hematological, bladder and esophageal cancer, respectively, and three target genes (<i>TP53, CCND1 and KRAS</i>) were common to all three types of cancer.
|
31444279 |
2019 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Upregulation of plasma miR-93-5p expression significantly increases the risk of esophageal cancer and is associated with poor prognosis. miR-93-5p transferred by exosomes promotes the proliferation of recipient esophageal cancer cells and affects the expression of PTEN and its downstream proteins p21 and cyclin D1.
|
29673440 |
2018 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Pin1 is a critical therapeutic and preventive target in esophageal cancer because of its positive regulation of β-catenin and cyclin D1.
|
28325828 |
2017 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To elucidate the molecular functions of cyclin D1 on EMT phenotypes and esophageal cancer radiosensitivity, we treated the radioresistant esophageal cancer cells (KYSE-150R) and parental cells (KYSE-150) with cyclin D1 small interfering RNA (siRNA).
|
26561473 |
2016 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We utilized a murine esophageal cancer cell line established from the ED-L2-cyclin D1;p53 mouse that was transduced to express a viral tumor antigen, the Human Papilloma Virus (HPV) E7 protein.
|
24810640 |
2014 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, S6 and S6 kinase 1 knockdown resulted in attenuation of viability by suppressing cyclin D1 expression in esophageal cancer cells.
|
22996377 |
2013 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Taken together, our results suggest that the CCND1 G870A polymorphism might not be a potential candidate for predicting esophageal cancer risk.
|
23661400 |
2013 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Promising markers that emerged for the prediction of overall survival in esophageal squamous cell cancer included VEGF (18 eligible studies, n=1476, HR=1.85, 95% CI, 1.55-2.21), cyclin D1 (12 eligible studies, n=1476, HR=1.82, 95% CI, 1.50-2.20), Ki-67 (3 eligible studies, n=308, HR=1.11, 95% CI, 0.70-1.78) and squamous cell carcinoma antigen (5 eligible studies, n=700, HR=1.28, 95% CI, 0.97-1.69); prognostic markers for esophageal adenocarcinoma included COX-2 (2 eligible studies, n=235, HR=3.06, 95% CI, 2.01-4.65) and HER-2 (3 eligible studies, n=291, HR=2.15, 95% CI, 1.39-3.33); prognostic markers for uncategorized ECs included p21 (9 eligible studies, n=858, HR=1.27, 95% CI, 0.75-2.16), p53 (31 eligible studies, n=2851, HR=1.34, 95% CI, 1.21-1.48), CRP (8 eligible studies, n=1382, HR=2.65, 95% CI, 1.64-4.27) and hemoglobin (5 eligible studies, n=544, HR=0.91, 95% CI, 0.83-1.00).
|
24206575 |
2013 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings suggested that CCND1 amplification and co-alternation of CCND1(+) /pRb(-) /ppRb(+) may play a crucial role in the prognostic evaluation of patients with esophageal cancer, and the patients with CCND1(+) /pRb(-) /ppRb(+) have the worst prognosis in all the patients.
|
22150974 |
2013 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The overall data suggest that CCND1 G870A variation might have an association with increased esophageal cancer susceptibility.
|
23020291 |
2012 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Results suggest that TC21 mediates its effects via the PI3K-Akt pathway, NF-κB and cyclin D1, and enhances chemoresistance in esophageal cancer cells.
|
22919244 |
2012 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We developed two mouse models of esophageal cancer by inoculating immunocompetent mice with syngeneic esophageal cell lines transformed by cyclin-D1 or mutant HRAS(G12V) and loss of p53.
|
21869822 |
2011 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer.
|
17912028 |
2007 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
In CCND1 G870A polymorphism, the AA genotype was marginally associated with higher risk of esophageal cancer (OR 1.5, 95%CI=0.98-2.4, P=0.05).
|
17561354 |
2007 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In CCND1 G870A polymorphism, the AA genotype was marginally associated with higher risk of esophageal cancer (OR 1.5, 95%CI=0.98-2.4, P=0.05).
|
17561354 |
2007 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
To determine whether cyclin D1 is subject to mutations that inhibit its nuclear export in human cancer, we have sequenced exon 5 of cyclin D1 in primary esophageal carcinoma samples and in cell lines derived from esophageal cancer.
|
16732330 |
2006 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Overexpression of cyclin D1 protein was identified in 37.5% of the specimens of esophageal tumors and 35% of gastric tumors, and overexpression of Her-2/neu protein in 12.5 and 7.5%, respectively.
|
16490596 |
2006 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To determine whether cyclin D1 is subject to mutations that inhibit its nuclear export in human cancer, we have sequenced exon 5 of cyclin D1 in primary esophageal carcinoma samples and in cell lines derived from esophageal cancer.
|
16732330 |
2006 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cyclin D1 overexpression in esophageal cancer from southern China and its clinical significance.
|
16051426 |
2006 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Ki67, p53, cyclin D1 and pRB expression may be useful biomarkers for assessing the risk of developing esophageal cancer.
|
16273238 |
2005 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study.
|
14966901 |
2004 |
|
Esophageal Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The CCND1-EMS1 locus on human chromosome 11q13 is amplified in esophageal cancer, bladder tumors, and breast cancer.
|
12739008 |
2003 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Increased DNA content and heteroploid rate, accumulation of p53 protein, and over-expression of p21, telomerase and cyclin D1 proteins were early molecular events during the development of esophageal cancer.
|
14606066 |
2003 |
|
Esophageal Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We examined the possible role of cyclin D1 overexpression on specific malignant properties of tumor cells using a series of eight human esophageal cancer cell lines that express different levels of cyclin D1.
|
12014632 |
2002 |
|
Esophageal Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Whereas L2D1(+) mice exhibit a histologic phenotype of oral-esophageal dysplasia, the combination of cyclin D1 expression and p53 deficiency results in invasive oral-esophageal cancer.
|
12235107 |
2002 |